Salud
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
![](https://univciencia.com/wp-content/uploads/2024/05/rt-ultimo4-MEZPMQ.jpeg)
In this randomized, controlled trial involving women in South Africa and Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection.
The New England Journal of Medicine: Search Results in Infectious Disease